Compare KFFB & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFFB | NNVC |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 37.9M |
| IPO Year | 2004 | 2008 |
| Metric | KFFB | NNVC |
|---|---|---|
| Price | $5.18 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.6K | ★ 375.6K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.52 | 10.00 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $15,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $0.85 |
| 52 Week High | $5.48 | $2.23 |
| Indicator | KFFB | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 57.43 | 48.51 |
| Support Level | $4.26 | $1.18 |
| Resistance Level | $5.48 | $1.63 |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 58.90 | 17.22 |
Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.